Probiotics may alleviate symptoms of hay fever, which may be related to bacteria in our gut and nose.

Published Date: 26 Apr 2023

The dreaded hay fever signs, including itchy eyes, sneezing, and a stuffy nose, have arrived for many people with the arrival of spring. Up to 42% of people experience hay fever, making it a widespread condition. Immune system overreaction is the cause of it.

Read Full News

Latest News

Blood Test Could Spot Gut Damage in Celiac Disease

A distinctive pattern of inflammatory proteins in the blood of adults with celiac disease reflects the severity of gut damage and may offer a noninvasive way to monitor disease activity.

Ustekinumab Biosimilar Switch Maintains Outcomes in Crohn's

Patients with Crohn's disease in remission who switch from reference ustekinumab to biosimilar versions maintain similar clinical success rates over 6 months to those continuing reference treatment.

Adding Radiotherapy to NAC Shows No Survival Benefit in PDAC

For patients with resectable pancreatic cancer, adding radiotherapy to neoadjuvant chemotherapy may improve pathological response, but that doesn’t translate into better outcomes.

Real-World Data Favor Upadacitinib in Bio-Exposed UC

A Portuguese real-world study finds that upadacitinib outperforms tofacitinib and ustekinumab — top-tier options after UC treatment failure — with higher remission rates at 16 and 52 weeks.

FDA Okays RAS Inhibitor Daraxonrasib for Pancreatic Cancer

Daraxonrasib is being hailed as a potential game changer for metastatic pancreatic cancer, roughly doubling survival vs chemotherapy in previously treated patients.

FDA Approves Zanidatamab Regimen for HER2-Positive GEA

Zanidatamab with tislelizumab and chemotherapy leads to overall survival of 26.4 months.

Todays Updates

Can 80 Gy Radiation Boost Survival in Prostate Cancer?

A modest increase in radiation dose improves progression-free survival over 10 years among men with high-risk prostate cancer — but the overall survival benefits found in a French trial are uncertain.

Todays Updates

Can 80 Gy Radiation Boost Survival in Prostate Cancer?

A modest increase in radiation dose improves progression-free survival over 10 years among men with high-risk prostate cancer — but the overall survival benefits found in a French trial are uncertain.

Latest News

A distinctive pattern of inflammatory proteins in the blood of adults with celiac disease reflects the severity of gut damage and may offer a noninvasive way to monitor disease activity.

Patients with Crohn's disease in remission who switch from reference ustekinumab to biosimilar versions maintain similar clinical success rates over 6 months to those continuing reference treatment.

For patients with resectable pancreatic cancer, adding radiotherapy to neoadjuvant chemotherapy may improve pathological response, but that doesn’t translate into better outcomes.

A Portuguese real-world study finds that upadacitinib outperforms tofacitinib and ustekinumab — top-tier options after UC treatment failure — with higher remission rates at 16 and 52 weeks.

Daraxonrasib is being hailed as a potential game changer for metastatic pancreatic cancer, roughly doubling survival vs chemotherapy in previously treated patients.

Zanidatamab with tislelizumab and chemotherapy leads to overall survival of 26.4 months.

News All Time

One Surgical Approach May Be Better for Complex Gallbladder Disease

Robotic cholecystectomy tied to reduced adverse outcomes over laparoscopic approach

You've Heard of Cyclospora. What Other Parasites Can You Catch From Food?

Experts describe some of the most common protozoa and worms

Iceberg Blamed in Diarrhea Outbreak; Masking Urged in Cities; DEA's Ketamine Probes

Health news and commentary gathered by MedPage Today staff

What's the Best Way to Test for Cyclospora Infection?

Microscopy and DNA tests are both viable, but sensitivity, cost, and availability vary

930 Dead in Outbreak; FDA Backtracks on Iceberg Lettuce; Chronic Cough Drug Fizzles

Health news and commentary gathered by MedPage Today staff

Novel Drug Shows Promise in Crohn's, Ulcerative Colitis

Duvakitug may be suitable for patients previously treated with advanced therapy

Lettuce Supplier Still the Focus in Cyclospora Outbreak, Despite Faulty Test Result

FDA says its investigation and outbreak data continue to point to Taylor Farms' iceberg lettuce

Singing for Chronic Belching; Excess Cancers in Crohn's; Dual Agonist for Liver Fat

News and commentary from the world of gastroenterology and hepatology

Inside the Intestinal Crypt: Untold Stories of Cyclospora

There's still much to learn about the parasite's past, present, and future

FDA Approves New Blood Test for Colon Cancer Screening

SimpleScreen CRC is indicated for adults 45 and up at average risk

Cyclospora Boosts Fears That Deadlier Foodborne Outbreaks Are Ahead

Food safety leaders across the U.S. are raising alarms over federal cuts

Diabetes and Pancreas Cancer; Crohn's Tied to Joint Infections; Hypnotherapy for IBS

News and commentary from the world of gastroenterology and hepatology

Intensified Pre-Op Chemoradiotherapy Fails in Locally Advanced Rectal Cancer

DFS at 3 years nearly identical with the addition of irinotecan, but with more toxicity

Michigan Reports First Two U.S. Deaths Related to Diarrhea-Causing Parasite

The CDC says cyclosporiasis is rarely deadly

Study Examines Link Between IBD and Psychiatric Disorders

Does psychiatric morbidity precede IBD onset or arise after diagnosis?

FIT-Based Screening Linked to Drop in Colorectal Cancer Mortality

Inflection point occurred around 2012, 3 years after screening program was implemented

Recommended News For You

Can Fasting Around Chemo Improve Ovarian Cancer Outcomes?

Medical debt in collections persists after cancer diagnosis

Glioblastoma cells can 'unstick' from their neighbors to become more deadly

Research has shown that Ga-68 FAPI PET enhances pancreatic cancer detection and staging.

In Acute Leukemia With Heavily Pretreated Patients, Menin Inhibitor Yields 63 Percent ORR.

Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.

How a new light-based cancer treatment could destroy tumors without harming healthy cells—using LEDs

Recommended Articles For You

Can We Repurpose BV-CHP for Better Outcomes in Peripheral T-Cell Lymphoma? 

Molecular & Genetic Oncology: Emerging Frontiers in 2025 

Intravenous Calcium for Reducing Blood Loss During Cesarean Delivery: A Review of Current Evidence 

Revolutionizing Lung Transplantation: The Promise of Donor-Specific Blood Transfusion 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The need for more Latinx participants in Alzheimer's trials is urgent.

2.

Study reveals crucial gaps in oral cancer awareness in Middle East and North Africa

3.

Disparities in use of MRI to detect prostate cancer: Race and location may influence testing

4.

In breast-conserving surgery, is micro-CT a useful tool for determining tumor margins?

5.

Study offers clearer picture of childhood brain tumor survival

1.

Revolutionizing Cancer Care: The Promise of Early Detection and Biomarkers

2.

The Oncologist’s Edge: Tools, Trials, and Tech Transforming Treatment

3.

Comprehensive Standards in Oncology for Modern Medicine

4.

Cardio-Oncology: Managing Heart Failure in Survivors of Cancer

5.

Practical Standards in Hematology for Healthcare Excellence

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment

2.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

3.

Efficient Management of First line ALK-rearranged NSCLC - Part VIII

4.

Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma

5.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot